Intravenous immunoglobulin (IVIG) and corticosteroids have been pivotal yet controversial agents in the management of acute myocarditis, particularly in pediatric populations. Despite decades of clinical use, the therapeutic efficacy and optimization of these treatments remain topics of intense investigation and debate. A groundbreaking systematic review and network meta-analysis, recently published in Pediatric Research, seeks to clarify the roles of IVIG and steroids in treating acute myocarditis in children, providing new insights that may influence future treatment protocols.
Acute myocarditis, characterized by inflammation of the heart muscle, poses a significant clinical challenge due to its variable presentation and unpredictable progression. In pediatrics, the stakes are especially high as this condition can lead to severe heart failure and long-term cardiac dysfunction in young patients. Current therapeutic strategies often include IVIG and steroids, which aim to modulate the immune response and reduce myocardial inflammation. However, the conflicting evidence regarding their effectiveness has hindered the development of standardized treatment regimens.
The study led by Thai, Kang, and Nguyen employed a robust network meta-analytical approach to synthesize existing data from randomized controlled trials (RCTs) and observational studies. This method allowed for indirect comparisons and ranking of treatments, providing a comprehensive overview beyond traditional pairwise meta-analysis. Their work included a detailed evaluation of short- and long-term outcomes, such as survival rates, recovery of cardiac function, and incidence of adverse effects associated with IVIG and steroid use.
One of the critical findings of this research was the inconclusive evidence supporting the superiority of either IVIG or steroids alone in improving survival outcomes for children suffering from acute myocarditis. While some studies suggest benefits in myocardial recovery with immune modulation, the overall data lack consistency. The network meta-analysis highlighted the heterogeneity in study designs, patient populations, and treatment protocols, which has historically limited the reliability of conclusions drawn from individual trials.
Notably, the analysis also challenged the assumption that combining IVIG and steroids would synergistically enhance therapeutic efficacy. Results showed that combination therapy did not significantly outperform monotherapies or standard care in critical endpoints. This revelation is pivotal, suggesting that the empirical use of combination therapy may not necessarily translate into improved clinical outcomes and should be re-evaluated in light of potential risks, such as immunosuppression and secondary infections.
Mechanistically, both IVIG and steroids act by tempering the immune system’s attack on the myocardium. IVIG is believed to neutralize pathogens and autoantibodies, regulate complement activation, and modulate cytokine release, thereby reducing inflammation. Steroids exert potent anti-inflammatory effects by inhibiting nuclear factor-kappa B (NF-κB) and other transcription factors that promote the expression of pro-inflammatory genes. Despite these theoretical benefits, how these agents influence the complex immunopathology of myocarditis remains incompletely understood.
The variability in clinical responses to IVIG and steroids may stem from differences in the underlying etiologies of myocarditis, which include viral infections, autoimmune triggers, and other inflammatory causes. This heterogeneity complicates the identification of patient subgroups that might benefit most from specific immunomodulatory treatments. The study emphasizes the urgent need for personalized medicine approaches, incorporating biomarkers and molecular diagnostics to tailor therapy to individual patient profiles.
Another significant component of the research involves the timing and dosing of immunomodulatory therapy. Early intervention is hypothesized to curb irreversible myocardial damage, yet the optimal therapeutic window remains elusive. The included studies exhibited considerable variation, with some initiating treatment rapidly after diagnosis and others employing delayed protocols. Dose regimens also fluctuated, particularly with steroid therapy, ranging from low maintenance doses to high-dose pulse therapies, further complicating outcome assessments.
Moreover, safety considerations play a crucial role in weighing the benefits and risks of IVIG and steroids. Immunosuppressive effects increase susceptibility to opportunistic infections and may precipitate other systemic complications. The meta-analysis underlined the necessity for vigilant monitoring and judicious use of these agents, especially in the pediatric population with immature immune systems and developing organs.
The authors underscore the limitations inherent to the current body of evidence. Many included studies have small sample sizes, inherent biases, and lack standardized definitions of myocarditis and treatment response. Heterogeneity in diagnostic criteria, such as reliance on endomyocardial biopsy versus imaging modalities, further complicates the synthesis of data. These gaps call for well-powered, multicenter randomized trials with harmonized protocols to generate high-quality evidence.
Emerging therapies beyond IVIG and steroids, such as biologics targeting specific cytokines or immune cells, represent promising avenues for future myocarditis management. However, the foundational understanding of efficacy derived from traditional agents like IVIG and corticosteroids remains indispensable. This study informs the clinical community of current uncertainties and highlights critical areas for research innovation.
In conclusion, the comprehensive analysis by Thai et al. reiterates that while IVIG and steroids are mainstays in acute pediatric myocarditis treatment, their definitive benefits remain unproven. The therapeutic landscape is fraught with challenges, including patient heterogeneity, treatment variability, and safety concerns. This pivotal work serves as a clarion call for precision medicine and rigorous clinical trials to elucidate optimal strategies, ultimately improving outcomes for children afflicted by this life-threatening condition.
As the cardiology and immunology fields advance, integrating cutting-edge genomic, proteomic, and immunophenotyping tools could revolutionize myocarditis treatment. By tailoring immunomodulatory therapy to the molecular and cellular profiles of individual patients, clinicians may enhance efficacy while minimizing adverse effects. Until such personalized interventions become standard, clinicians must carefully weigh the equivocal evidence surrounding IVIG and steroids, making informed decisions guided by clinical judgment and patient-specific factors.
Given the disease’s complexity and the high stakes involved in pediatric care, multidisciplinary collaboration among cardiologists, immunologists, infectious disease specialists, and intensivists is paramount. Together, they can forge innovative pathways for research and clinical practice, ensuring that therapeutic advancements translate into real-world benefits.
This systematic review and network meta-analysis not only refines our understanding of established therapies but also sets the stage for future investigations to unlock the full therapeutic potential in pediatric acute myocarditis. It is a significant step toward evidence-based, patient-centered care in a challenging and evolving clinical domain.
Subject of Research: The therapeutic effectiveness of intravenous immunoglobulin (IVIG) and steroids in the treatment of acute myocarditis in children.
Article Title: Effect of intravenous immunoglobulin and steroids in acute myocarditis in children: a systematic review and network meta-analysis.
Article References:
Thai, T.B.T., Kang, YN., Nguyen, H.S. et al. Effect of intravenous immunoglobulin and steroids in acute myocarditis in children: a systematic review and network meta-analysis. Pediatr Res (2026). https://doi.org/10.1038/s41390-025-04655-0
Image Credits: AI Generated
DOI: 10 February 2026
Tags: acute myocarditis clinical guidelineschallenges in pediatric myocarditiscorticosteroids in acute myocarditisimmune modulation in heart diseaseIVIG treatment for pediatric myocarditislong-term effects of myocarditis in childrennetwork meta-analysis in cardiologyoptimizing myocarditis treatment protocolspediatric heart inflammation managementrandomized controlled trials on myocarditissystematic review on myocarditis therapiestherapeutic efficacy of IVIG and steroids
